Kathryn Dempsey, MD
Dermatology · Mobile, ALNPI 1861713273
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $43,500 of the $48,475 with a category attached, or 89.7%. Galderma Laboratories, L.p. accounts for 94.1% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2024 at $25,900 and has fallen 79.3% since, to $5,354 in 2025.
Across 185 payments — averaging $262.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Galderma Laboratories, L.p.$46K
- AbbVie$718
- Sun Pharmaceutical Industries Inc.$383
- Hill Dermaceuticals, Inc.$284
- Johnson & Johnson$267
- Novartis$256
- plus $974 from 19 others
What the payments were for
- Speaking & faculty fees$43,50090%
- Travel & lodging$1,1572%
- Food & beverage$3,6317%
- Education$1870%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Galderma Laboratories, L.p. | 67 | $45,592 |
| AbbVie(2 entities) | 30 | $718 |
| Sun Pharmaceutical Industries Inc. | 19 | $383 |
| Hill Dermaceuticals, Inc. | 1 | $284 |
| Johnson & Johnson | 12 | $267 |
| Novartis | 9 | $256 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 4 | $164 |
| Sanofi | 8 | $135 |
| Pfizer | 8 | $125 |
| UCB, Inc. | 4 | $82 |
| Sanofi-aventis U.S. LLC | 1 | $72 |
| Regeneron Healthcare Solutions, Inc. | 3 | $52 |
| Incyte Corporation | 3 | $49 |
| Dermavant Sciences, Inc. | 3 | $47 |
| E.r. Squibb & Sons, L.L.C. | 2 | $44 |
| Lilly USA, LLC | 2 | $36 |
| Arcutis Biotherapeutics, Inc. | 1 | $26 |
| Merz North America, Inc. | 1 | $23 |
| Mayne Pharma Commercial LLC | 1 | $21 |
| LEO Pharma Inc. | 1 | $18 |
| Boehringer Ingelheim | 1 | $17 |
| Dermira, Inc. | 1 | $17 |
| Botanix SB Inc | 1 | $16 |
| Almirall LLC | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$48,475 in reported general payments places this provider in the 85th percentile of 168 dermatology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cosentyx Sensoready (2 Pens)Secukinumab | 12 | $86,427 |
| EliquisApixaban | 12 | $6,451 |
| Clobetasol Propionate | 51 | $1,982 |
| Fluorouracil | 21 | $1,767 |
| Acitretin | 11 | $1,254 |
| ValacyclovirValacyclovir Hcl | 43 | $1,088 |
| Ketoconazole | 57 | $979 |
| Fluocinonide | 22 | $803 |
| Doxycycline Hyclate | 39 | $786 |
| Mupirocin | 69 | $654 |
| Metronidazole | 14 | $639 |
| Hydroxychloroquine Sulfate | 29 | $498 |
| Triamcinolone Acetonide | 36 | $307 |
| MethotrexateMethotrexate Sodium | 17 | $295 |
| Minoxidil | 24 | $204 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $125 | $6,45112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 168 dermatology providers in Alabama.
Other dermatology in Mobile
- John VanloockMobile$1.4M
- Thomas BenderMobile$142K
- Ryan RamagosaMobile$87K
- Virginia ReederMobile$22K
- Angel AllenMobile$11K
- Dena HowellMobile$8K
- James KrellBirmingham$944K
- Julie HarperBirmingham$920K
- Eric BaumGadsden$896K
- Corey HartmanBirmingham$573K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.